The World’s Second Wearable Insulin Pump
EOFlow Co., a provider of wearable drug delivery solutions, announced on Oct. 14 that the company has completed enrollment of the first patient in a clinical study on type 2 diabetes for its wearable insulin pump “EOPatch” in Korea.
This study is conducted at 10 university-hospitals, seven of which are in Seoul metropolitan area and the other three in non-metropolitan area. The company said that the study would ultimately enroll 136 people with type 2 diabetes. This study is supported by Korean government research grants and is known to be the largest clinical study for insulin pump therapy in Korea.
The company said that notwithstanding the COVID-19 situation, there were many applicants for participation in the clinical study. It expects the recruitment of patients to proceed smoothly as planned.
This clinical study is a multicenter trial which aims to validate the clinical safety and efficacy of EOPatch for treating people with type 2 diabetes, thus expanding its user base beyond type 1 diabetes patients. For the near term, the company is focused on accelerating the patient registration process.
Recently, the company has begun to export the world’s second wearable insulin pump, EOPatch, to the European market.
EOPatch is a new-generation wearable insulin pump that resolved the problem of long infusion lines in existing pumps, which limit free movement of users. It allows insulin injections for up to 84 hours or 3.5 days.
In 2019, the company signed a US$127 million deal with Menarini, one of the world's 50 largest pharmaceutical companies, to export EOPatch to Europe for five years.